CA-POSIFLEX
5.1.2022 18:02:06 CET | Business Wire | Press release
Posiflex is pleased to join National Retail Federation’s Big Show for 2022 and will be showcasing its latest point-of-sale solutions in booth #5919. After a two-year-long hiatus from a live NRF show, anticipation is at an all-time high, and Posiflex is excited to exhibit its full line of point-of-sale (POS) terminals, kiosks, tablets and more—along with a few surprises—optimized for retailers in search of powerful and flexible post-pandemic solutions for their operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220105005004/en/
In addition, Posiflex will showcase a new line of POS terminals for today’s retail demands, including the versatile XT7315 , and exciting, fresh models from the new RT6000 Series: the RT6015 and RT6016 .
The XT7315 comes with a wide selection of processors that can suit virtually any point-of-sale requirement. Running on Windows 10 IoT Enterprise OS platform, the XT7315 is housed in a stylish, durable exterior and has a well-designed base that allows for optimal cable management. With its choice of processors, plus a multi-position folding base and a fanless design, the XT7315 continues the excellence of quality and performance that the line of Posiflex XT Series is well-known for.
The new RT6000 Series includes two models: the RT6015 and RT6016, both providing a selection of Intel processors geared for maximum performance and uptime. The main difference between the two models is the display size, with the RT6015 having a 15”/4:3 standard-ratio touch screen display and the RT6016 having a 15.6”/16:9 widescreen-ratio touch screen display. Running on Windows 10 IoT Enterprise and sporting the same exceptional characteristics from the RT Series family, including sleek aesthetics, durability, performance, and reliability, the Posiflex RT6000 Series is an ideal fit for Retail, Hospitality or Specialty-Service establishments.
“With rigorous HALT/HASS testing and total in-house manufacturing that all our products experience, our new XT7315 and RT6000 terminals extend the Posiflex legacy of providing top-notch point-of-sale hardware for today’s challenging atmosphere and customers’ demands,” says Doyle Ledford, VP of Sales & Marketing for Posiflex. “We look forward to introducing these exceptional products along with the rest of our latest solutions at NRF 2022.”
About Posiflex
Since 1984, Posiflex has designed and manufactured award-winning POS terminals and peripherals. Posiflex has since grown exponentially to provide not only full-service POS stations, but also versatile self-service kiosks, state-of-the-art mobile tablets, and scalable embedded PC solutions. Renowned worldwide in the retail and hospitality industries, Posiflex is a proven leader in POS hardware for Windows and Android OS. More than 30 patents and numerous awards have been won for product innovation, design, and reliability. https://www.posiflexusa.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220105005004/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom